Vaccines Human Subject Research - Annual
Forecasted
Vaccines Human Subject Research - Annual supports external sponsors’ human subject studies of vaccine protection, impact, and disease burden to deepen understanding of RSV, shingles, meningococcal, and pneumococcal disease.
Funder: GSK
Due Dates (Anticipated): January 2027 (2026 Cycle protocol draft) | September 2027 (submission close)
Funding Amounts: Funding, product, or both may be provided; no award amount is listed
Summary: Supports externally sponsored human subject research on vaccine impact, protection, and disease burden.
Key Information: Sponsors must agree to publish results and grant GSK a license to study outputs.
Description
GSK’s Supported Studies Programme considers externally sponsored human subject research in vaccine-related areas. Its annual vaccines call highlights real-world effectiveness and impact of Arexvy in adults at increased risk of RSV disease; sub-clinical varicella zoster virus reactivation and longer-term Shingrix protection in immunocompromised people; and meningococcal disease burden, 4CMenB-induced antibodies, cross-protection, and dosing schemes.
The programme also considers the evolving serotype-specific burden of pneumococcal disease in adults and children, including epidemiological or economic endpoints. GSK can support Investigator Sponsored Studies designed and managed by an external sponsor, or Supported Collaborative Studies to which GSK also contributes study design and deliverables.
